Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
SEC ownership of Elevation Oncology, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001783032.
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
5/18
Latest evidence
23 Jul 2025
- Parsed ownership sources
- 13D/G and 3/4/5
- Largest SEC-reported holder
- BIOTECHNOLOGY VALUE FUND L P
- Latest 13D/G holder
- BIOTECHNOLOGY VALUE FUND L P
- Latest parsed ownership date
- 23 Jul 2025
- Issuer CIK
- 0001783032
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Elevation Oncology, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
5/18
Latest evidence
23 Jul 2025
13D/G
3/4/5
Lead comparable stake: 7%
13 rows are not safely comparable across share classes.
13D/G row: BIOTECHNOLOGY VALUE FUND L P
Showing 1-8 of 18 holder rows.
Quick read
BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 7%.
5 of 18 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership
Top 5
BIOTECHNOLOGY VALUE FUND L P
7%
TANG CAPITAL MANAGEMENT LLC
5%
VANGUARD GROUP INC
4.4%
GOLDMAN SACHS GROUP INC
2.8%
BlackRock, Inc.
0.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 18 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
7%
|
$1,642,800
4,440,000 shares
|
$0 | 31 Mar 2025 |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
|
5%
|
$1,183,700
3,115,000 shares
|
-$1,112,990 | 30 Jun 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.4%
|
$965,717
2,610,045 shares
|
$0 | 31 Dec 2024 |
| GOLDMAN SACHS GROUP INC |
13D/G
THE GOLDMAN SACHS GROUP, INC.
|
2.8%
|
$622,842
1,683,356 shares
|
$0 | 31 Dec 2024 |
| BlackRock, Inc. |
13D/G
|
0.6%
|
$135,478
369,048 shares
|
-$1,025,726 | 30 Jun 2025 |
| Qiming U.S. Healthcare Fund II, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,208,772
2,370,142 shares
|
— | 29 Jun 2021 |
| Vertex Global HC Fund II Pte. Ltd. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,176,897
2,307,642 shares
|
— | 29 Jun 2021 |
| Cormorant Asset Management, LP |
3/4/5
Former 10% Owner
|
—
class O/S missing
|
$1,138,916
2,233,168 shares
|
— | 29 Jun 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Elevation Oncology, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Qiming U.S. Healthcare Fund II, L.P.
Net 12M change
$0
Latest report
23 Jul 2025
Recent insider transactions for Elevation Oncology, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Alan B. Sandler | ELEV | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -125,000 | 0 | 23 Jul 2025 | Direct | ||
| Darcy Mootz | ELEV | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -125,000 | 0 | 23 Jul 2025 | Direct | ||
| Steve Elms | ELEV | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -148,095 | 0 | 23 Jul 2025 | See footnote | ||
| Timothy P. Clackson | ELEV | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -47,330 | 0 | 23 Jul 2025 | The Timothy P. Clackson Irrevocable GST Trust of 2020 | ||
| Timothy P. Clackson | ELEV | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -116,857 | 0 | 23 Jul 2025 | Direct | ||
| Julie M. Cherrington | ELEV | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -125,000 | 0 | 23 Jul 2025 | Direct | ||
| R. Michael Carruthers | ELEV | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -164,187 | 0 | 23 Jul 2025 | Direct | ||
| Tammy Furlong | ELEV | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -37,957 | 0 | 23 Jul 2025 | Direct | ||
| Tammy Furlong | ELEV | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -828,387 | 0 | 23 Jul 2025 | Direct | ||
| Joseph J. Ferra Jr. | ELEV | Common Stock | Tax liability | -3.09% | -4,627 | 145,085 | 16 Jun 2025 | Direct | ||
| Joseph J. Ferra Jr. | ELEV | Common Stock | Options Exercise | 9.16% | 12,560 | 149,712 | 16 Jun 2025 | Direct | ||
| Joseph J. Ferra Jr. | ELEV | Restricted Stock Unit | Options Exercise | -100% | -12,560 | 0 | 16 Jun 2025 | Direct | ||
| Alan B. Sandler | ELEV | Stock Option (Right to Buy) | Award | 35,000 | 35,000 | 05 Jun 2025 | Direct | |||
| Darcy Mootz | ELEV | Stock Option (Right to Buy) | Award | 35,000 | 35,000 | 05 Jun 2025 | Direct | |||
| Steve Elms | ELEV | Stock Option (Right to Buy) | Award | 35,000 | 35,000 | 05 Jun 2025 | See footnote | |||
| Timothy P. Clackson | ELEV | Stock Option (Right to Buy) | Award | 35,000 | 35,000 | 05 Jun 2025 | Direct | |||
| Julie M. Cherrington | ELEV | Stock Option (Right to Buy) | Award | 35,000 | 35,000 | 05 Jun 2025 | Direct | |||
| R. Michael Carruthers | ELEV | Stock Option (Right to Buy) | Award | 35,000 | 35,000 | 05 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.